Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an incidence of 1:5000. Recurrent, spontaneous epistaxis is the most common presenting symptom. Severity of epistaxis varies widely, from mild, self-limited nosebleeds to severe, life-threatening nasal hemorrhage. Treatment of HHT-related epistaxis presents a challenge to the otolaryngologist due to the recurrent, persistent nature of epistaxis often requiring multiple treatments. Treatment modalities range from conservative topical therapies to more aggressive surgical treatments.
Department of Otolaryngology - Head and Neck Surgery, Oregon Sinus Center, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: nsautter@gmail.com.
Nathan B
NB
Sautter
Department of Otolaryngology - Head and Neck Surgery, Oregon Sinus Center, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA.
Timothy L
TL
Smith
D003131:Combined Modality Therapy / Q000379:methods; D004724:Endoscopy / Q000009:adverse effects / Q000379:methods; D004844:Epistaxis / Q000601:surgery*; D006488:Hemostasis, Surgical / Q000379:methods*; D006489:Hemostatic Techniques; D006490:Hemostatics / Q000494:pharmacology*; D006801:Humans; D010043:Outcome and Process Assessment, Health Care; D055502:Secondary Prevention / Q000379:methods; D012720:Severity of Illness Index; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications*
D006490:Hemostatics
Bevacizumab; Epistaxis; Hereditary hemorrhagic telangiectasia (HHT); Laser photocoagulation; Osler-Weber-Rendu; Septodermoplasty; Young’s procedure